Nifekalant is a class III antiarrhythmic agent within the pyrimidine derivative family, indicated for the clinical management of ventricular arrhythmias in patients with structural heart disease. By blocking… Read more
Nifekalant is a class III antiarrhythmic agent within the pyrimidine derivative family, indicated for the clinical management of ventricular arrhythmias in patients with structural heart disease. By blocking potassium channels and inhibiting calcium influx, this medication works to stabilize cardiac electrical activity. Laboratories utilize this category of pharmaceutical reference standards to perform essential quality control, method validation, and impurity profiling. The available selection includes the hydrochloride salt form, which serves as a primary standard, alongside specific degradants such as N-Nitroso Nifekalant for monitoring impurity profiles. Furthermore, stable isotope labelled compounds like Nifekalant-d4 are critical for use as internal standards in liquid chromatography-mass spectrometry (LC-MS) assays, ensuring accurate quantification and tracing of the drug and its metabolites in complex biological matrices. These high-quality analytical materials support precise testing protocols throughout pharmaceutical research and development.